Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
– Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company –
– Expanded and strengthened Comera’s global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology –
Related news for (CMRA)
- Comera Life Sciences Announces Process Exploring Strategic Alternatives
- Comera Life Sciences Announces Process Exploring Strategic Alternatives
- Comera Life Sciences Appoints Dorothy Clarke to Board of Directors
- Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference